Table 6.
Cytotoxicity of NLCs for mammalian cells (L 929 and Hep G2)
| Formulate | L 929 | HepG2 | ||||
|---|---|---|---|---|---|---|
| 100 µg/mL | 10 µg/mL | 1 µg/mL | 100 µg/mL | 10 µg/mL | 1 µg/mL | |
| NLC O’ | 10.0 ± 1.6 | 5.6 ± 3.2 | 5.7 ± 5.4 | 9.5 ± 8.8 | 2.7 ± 4.7 | 2.4 ± 4.1 |
| NLC 5′ | 5.0 ± 4.5 | 3.9 ± 3.7 | 3.7 ± 3.6 | 1.5 ± 2.7 | 0.3 ± 0.6 | 0.2 ± 0.1 |
| NLC 10’ | 4.9 ± 4.3 | 3.2 ± 3.0 | 3.4 ± 3.6 | 1.2 ± 2.1 | 1.9 ± 1.6 | 5.4 ± 5.5 |
| NLC 20‘’ | 5.3 ± 9.2 | 2.6 ± 4.4 | 2.2 ± 2.4 | 1.6 ± 0.8 | 0.5 ± 0.5 | 0.4 ± 0.5 |
| NLC 30’ | 3.1 ± 1.8 | 0.3 ± 0.5 | 1.9 ± 3.3 | 4.9 ± 8.5 | 0.1 ± 0.1 | 0.7 ± 1.3 |
ATCC = American Type Culture Collection; Hep G2 = human liver hepatocarcinoma cells ATCC; L 929 = murine L-929 fibroblasts (NCTC clone 929); NLC = nanostructured lipid carriers; WST = water-soluble tetrazolium test. Data reported as percentage of killed cells (WST test).